While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access

Prime Therapeutics experts examine how GLP-1 discontinuation trends shape benefit strategies, patient outcomes and long-term affordability

cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...